SUN PHARMA ADV.RES.CO.LTD Intrinsic Value
SPARC · Healthcare · Current price ₹204.19
Is SUN PHARMA ADV.RES.CO.LTD undervalued?
DocStoX estimates the fair value of SUN PHARMA ADV.RES.CO.LTD at ₹1,351 per share, versus the current market price of ₹204. That puts the stock about +561.8% below our fair-value estimate, which we read as "Strong Buy". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Relative P/E (₹1,450), Graham floor (₹210), Analyst target (₹2,040). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹210 (bear) to ₹1,351 (base) to ₹2,040 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹204 versus an intrinsic value of ₹1,351, SUN PHARMA ADV.RES.CO.LTD currently offers +561.8% of margin.
More on SUN PHARMA ADV.RES.CO.LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.